## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**

# Naldemedine for treating opioid-induced constipation [ID1189]

### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<ul><li>Company</li><li>Shionogi (naldemedine)</li></ul>	<ul><li>General</li><li>All Wales Therapeutics and Toxicology</li></ul>
<ul> <li>Snionogi (naidemedine)</li> <li>Patient/carer groups</li> <li>Action on Pain</li> <li>Black Health Agency</li> <li>Bladder and Bowel Community</li> <li>Bladder and Bowel UK</li> <li>Cancer Black Care</li> <li>Cancer Equality</li> <li>Guts UK</li> <li>HAWC</li> <li>Helen Rollason Cancer Charity</li> <li>IBS Network</li> <li>Independent Cancer Patients Voice</li> <li>Macmillan Cancer Support</li> <li>Maggie's Centres</li> <li>Marie Curie</li> </ul>	<ul> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Alliance</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> </ul>
<ul> <li>Muslim Council of Britain</li> <li>Pain Concern</li> <li>Pain Relief Foundation</li> <li>Pain UK</li> </ul>	<ul> <li>Scottish Society of Gastroenterology</li> <li>Welsh Health Specialised Services Committee</li> </ul>
<ul> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Tenovus Cancer Care</li> <li>Wellbeing of Women</li> <li>Women's Health Concern</li> <li>Professional groups</li> <li>Association for Continence Advice</li> <li>Association of Cancer Physicians</li> <li>Association of Coloproctology of Great Britain and Ireland</li> <li>British Geriatrics Society</li> <li>British Psychosocial Oncology Society</li> <li>British Society of Gastroenterology</li> </ul>	<ul> <li>Possible comparator companies</li> <li>Actavis UK (glycerol suppositories, bisacodyl, lactulose, senna)</li> <li>Cardinal Health Martindale Products (glycerol suppositories)</li> <li>Concordia International (methylcellulose)</li> <li>Dr. Reddy's lab (bisacodyl)</li> <li>Hermal (ispaghula husk, glycerol suppositories)</li> <li>Intrapharma (lactulose)</li> <li>Kyowa Kirin (naloxegol)</li> <li>Laboratorios Casen Fleet (sodium dihydrogen phosphate dehydrate, disodium hydrogen phosphate</li> </ul>

National Institute for Health and Care Excellence

Matrix for the technology appraisal of naldemedine for treating opioid-induced constipation [ID1189]

Issue date: April 2019 Page 1 of 4

Consultees	Commentators (no right to submit or
	appeal)
<ul> <li>Cancer Research UK</li> <li>Primary Care Society for Gastroenterology</li> <li>Royal College of General Practitioners</li> <li>Royal College of Pusthologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>UK Clinical Pharmacy Association</li> <li>UK Continence Society</li> <li>UK Health Forum</li> <li>UK Oncology Nursing Society</li> </ul> Others <ul> <li>Department of Health</li> <li>NHS Brighton &amp; Hove CCG</li> <li>NHS England</li> <li>NHS North Hampshire CCG</li> <li>Welsh Government</li> </ul>	dodecahydrate enema)  Meda Pharmaceuticals (macrogol, senna)  Mylan products (lactulose)  Napp Pharmaceuticals (naloxone-oxycodone)  Norgine Pharmaceuticals (sterculia/ frangula, macrogol, docusate sodium enema)  Novartis (senna)  Orbis Consumer Products (glycerol suppositories)  Pinewood Healthcare (sodium citrate enema)  Reckitt Benckiser Healthcare (senna)  Sandoz (lactulose)  Sanofi (bisacodyl, docusate, macrogol sodium picosulfate)  Stirling Anglian (macrogol)  Swedish Orphan Biovitrum (methylnaltrexone bromide)  Teva UK (lactulose)  Thornton & Ross (macrogol, magnesium hydroxide, glycerol suppositories, senna)  UCB Pharma (sodium citrate enema, docusate)  Relevant research groups  Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group  Institute of Cancer Research  MRC Clinical Trials Unit  National Cancer Research Network  National Institute for Health Research  Associated Public Health groups  Public Health England  Public Health Wales

Issue date: April 2019 Page 2 of 4

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: April 2019 Page 3 of 4

### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

National Institute for Health and Care Excellence Matrix for the technology appraisal of naldemedine for treating opioid-induced constipation [ID1189]

Issue date: April 2019 Page 4 of 4

-

<sup>&</sup>lt;sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.